Stepwise regression analysis of the determinants of blood tacrolimus concentrations in Chinese patients with liver transplant

Medicinal Chemistry

Volumn 5, Issue 3, 2009, Pages 301-304

  Jin, Z ^a   Zhang, W X ^a   Chen, B ^a   Mao, A W ^a   Cai, Wei Min ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Chinese; CYP3A5; Liver transplantation; MDR1; Stepwise regression analysis; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT; REGRESSION ANALYSIS; SPLEEN; ADOLESCENT; AGE DISTRIBUTION; AGED; ASIAN; BLOOD; CHINA; GENETICS; MIDDLE AGED; SEX RATIO; TIME;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SEX DISTRIBUTION; TACROLIMUS; TIME FACTORS; TISSUE DONORS;

EID: 67651183907     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609788185918     Document Type: Article

References (8)

1. Rossi, G.; Reggiani, P.; Orsenigo, R.; Leoni, L.; Caccamo, L.; Doglia, M.; Gatti, S.; Maggi, U.; Paone, G.; Galmarini, D.; Fassati. L.R. Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. Transplant. Proc., 1998, 30, 1391-1393.
2. Jain, A.; Kashyap, R; Kramer, D.; Dodson, F.; Hamad, I.; Starzl, T.E.; Fung, J.J. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil:complete report on 350 primary adult liver transplantations. Transplant. Proc., 2001, 3, 1342-1344.
3. Kamdem, L.K.; Streit, F.; Zanger, U.M.; Brockmöller, J.; Oellerich, M.; Armstrong, V.W.; Wojnowski, L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem., 2005, 51, 1374-1381.
4. Zheng, H.; Webber, S.; Zeevi, A.; Schuetz, E.; Zhang, J.; Bowman, P.; Boyle, G.; Law, Y.; Miller, S.; Lamba, J.; Burckart, G.J. Tacrolimus dosing in paediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant., 2003, 3, 477-483.
5. Jin, Z.; Zhang, W.X.; Mao, A.W.; Chen, H.; Gu, Z.D.; Cai, W.M. Relationship between CYP3A5 and MDR1 gene polymorphism and blood concentration of tacrolimus in Chinese liver transplant patients. Chin. Pharmaceutical. J., 2008, 43, 649-653.
6. Tuteja, S.; Alloway, R.R.; Johnson, J.A.; Gaber, A.O. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation, 2001, 71, 1303-1307.
7. Fredericks, S.; Holt, D.W.; MacPhee, I.A. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am. J. Pharmacogenomics, 2003, 3, 291-301.
8. Saeki, T.; Ueda, K.; Taniqawara, Y.; Hori, R.; Komano, T. Human P-glycoprotein transports eyelosporin A and FK506. J. Biol. Chem., 1993, 268, 6077-6080.